IPercept's 'machine fitness tracker' pulls in $17M for industrial AI

IPercept, a Stockholm-based company that builds AI-driven machine fitness tracking tools for industrial equipment, has raised a $17M Series A. The round was announced September 29, 2026, and is the company's first disclosed funding round in the tracked data — bringing its cumulative total raised to $17M.

The product is a "machine fitness tracker" for industrial machinery: an AI-enabled way to monitor machine condition and performance. IPercept targets manufacturers and machine operators that want better visibility into asset health and maintenance needs. Its stated differentiator is packaging machine-health analytics into a fitness-tracking-style workflow for industrial machinery — borrowing the consumer wearable metaphor and applying it to factory floor assets.

Investors in the round were not disclosed, so there is no named lead to credit for the deal. The company also has not stated how it intends to deploy the proceeds.

The raise places IPercept in the enterprise AI and predictive maintenance category, among the tools vendors selling condition monitoring and asset-health analytics to industrial buyers. That is a crowded and well-capitalized corner of the market, tracked alongside far larger peers in enterprise AI such as Helsing ($4.5B total raised), ServiceNow ($4.1B), Thrive Holdings ($3.0B), Isomorphic Labs ($2.6B) and Motive ($1.9B). Against those totals, IPercept's $17M is early-stage money, consistent with a company that has only one disclosed round on record.

What separates the Swedish company in its own framing is the packaging rather than the underlying category: instead of positioning as a generic predictive maintenance platform, it sells a monitoring device-plus-software experience built around a fitness-tracking workflow, aimed at the people running machines day to day rather than at data science teams.

For now, the open questions are the ones the announcement leaves unanswered: who wrote the check, and what the $17M is meant to buy. Neither was disclosed.